• Ongoing phase 3 trial with up to 450 patients, including RRMM patients who are refractory to lenalidomide
  • Direct comparison with pomalidomide in patients treated with IMiDs and PIs, and who have become refractory to their last line of therapy
  • The trial is designed to demonstrate benefit in comparison with pomalidomide
  • To obtain approval in Europe, the only requirement is to demonstrate that melflufen has the same benefit
  • Started in Q2 2017 with last patient in expected in Q1 2020